AlenMed

Treatment in Germany

EN

Mon–Fri 9:00–21:00 · Sat 10:00–18:00 (CET)
+49 176 61975550 — daily until 23:00

Dendritic Cell Therapy in Germany: How the Cancer Vaccine Is Made and Where It Stands

Updated

Dendritic cell vaccine preparation process diagram

Cancer vaccines made from a patient’s own immune cells are produced in Germany, but they are not standard care: this is an add-on method with limited evidence of benefit. Families often read about a “personal cancer vaccine made from your own cells” after surgery or chemotherapy and want to know whether it is real, whom it helps and how to get it.

Dendritic cell therapy in Germany is an individual vaccine made from the patient’s own immune cells, meant to teach the immune system to recognise the tumour; it is used alongside surgery, radiotherapy or drug treatment, not instead of them, and its benefit is still being studied. Below: the method, the evidence, the process and the costs. Other options are covered on the page on cancer treatment in Germany.

How dendritic cells work

Dendritic cells are the immune system’s scouts: they pick up fragments of foreign or altered proteins and show them to T cells, which then attack cells carrying the same fragments. The scouts sit in the skin, mucous membranes and other tissues and carry their catch to the nearest lymph nodes, where they brief the T cells.

The vaccine aims to give the immune system many trained scouts at once, all carrying markers of this particular tumour. But tumours defend themselves: they suppress immune cells around them, so T cells that reach them may simply stop working. The vaccine is therefore not a guarantee, and an immune response in blood tests does not mean the tumour will shrink. Other ways of enlisting the immune system, including checkpoint inhibitors, are explained on the cancer immunotherapy page.

How the vaccine is made: from blood sample to injection

The vaccine is made from the patient’s own blood, starting with leukapheresis: an outpatient procedure in which a machine separates white blood cells from the blood and returns the rest. The patient sits or lies for several hours while blood usually flows from one arm through the machine and back into the other. Most people mainly notice the needle and the long wait, with staff watching throughout.

In the laboratory, monocytes from these cells are grown into dendritic cells, loaded with tumour markers – antigens from the patient’s own tumour tissue or synthetic peptides (man-made protein fragments) – and tested for sterility and viability. Everything happens in a certified clean-room laboratory working to GMP (good manufacturing practice) and takes two to three weeks. Under the German Medicinal Products Act (Arzneimittelgesetz), this individually made medicine may only be produced with an official manufacturing authorisation; the usual exemption for doctors preparing medicines for their own patients does not apply to advanced therapy medicinal products such as this one.

The vaccine is injected under or into the skin near lymph nodes in several doses on a schedule, sometimes followed by boosters, with blood tests between visits. University hospitals, for example, run GMP laboratories for cell therapy: at University Hospital Würzburg, Prof. Matthias Eyrich heads cell therapy and the GMP laboratory at the Centre for Cellular Immunotherapy.

What studies show and who is considered

Studies show that dendritic cell vaccines are generally safe and can trigger an immune response against the tumour, but their clinical benefit has been limited. They have been studied for decades in melanoma, renal cell carcinoma, glioblastoma, prostate cancer, breast cancer and other tumours, with mixed results: in randomised phase III trials in melanoma after surgery, prostate cancer and renal cell carcinoma, adding the vaccine did not help patients live longer or stay recurrence-free for longer. Outside clinical trials, the method is not part of standard treatment guidelines. A recent review of dendritic cell vaccine trials explains why tumours blunt the effect and which combinations are being tested.

The method is usually discussed when the main tumour has been removed or only a small remnant is left, because a large tumour suppresses immunity more strongly. A reasonably good general condition and normal blood counts are needed, as the vaccine works only through the patient’s own immune system, and many protocols also need tumour tissue to load the cells. A clinical trial is often the most transparent route. The Paul-Ehrlich-Institut, the federal authority for cell-based medicines, warns against commercial offers of unauthorised products, including dendritic cell therapies for cancer, and advises using only authorised products or approved clinical trials.

The vaccine is generally well tolerated: typical reactions are redness, swelling or itching at the injection site and, briefly, a raised temperature, tiredness or flu-like aches. During leukapheresis some people feel tingling around the lips or in the fingers from the solution that stops blood clotting in the machine; the team deals with it at once by slowing the procedure or giving calcium. The vaccine is usually not given, or is postponed, in patients who need ongoing immunosuppressive medicines, including high-dose corticosteroids, have an active autoimmune disease or a severe infection, are pregnant or are in very poor general condition; the final decision is the doctor’s.

Standard treatment of glioblastoma and its clinical trials are explained on the page on glioblastoma treatment in Germany. Hyperthermia in cancer treatment is a separate method with its own page.

Process and costs for international patients

For international patients, treatment usually takes several trips, and the clinic calculates the cost individually. An oncologist first reviews reports and histology and holds a video consultation; if a vaccine is an option, the patient comes for examinations and leukapheresis. Preparation takes two to three weeks, spent in Germany or at home, followed by injection visits on schedule and sometimes boosters.

The course cost depends on the number of injections, laboratory work and accompanying diagnostics, and is confirmed in the clinic’s official cost estimate (Kostenvoranschlag). For the diagnostic part, these prices are known; details are on the diagnostics prices page.

  • ultrasound in clinics — about €130–150;
  • doctor’s consultation on the results — from €130;
  • basic MRI — about €800 (with contrast €900–1,000);
  • CT — about €500 (€550 with contrast).

Frequently asked questions

How much does dendritic cell therapy cost in Germany?

There is no fixed price: the course cost depends on the number of injections, laboratory work and examinations, and the clinic states it in an official cost estimate after reviewing the records; only the diagnostic prices above are known in advance. As this is not standard care, international patients usually pay for it themselves, so check reimbursement beforehand; the Paul-Ehrlich-Institut urges caution with expensive offers that insurers do not cover.

What is the success rate of dendritic cell therapy?

There is no reliable success rate. Studies differ widely in how the vaccine is made and in tumour type and stage, and in several late-stage comparative trials the vaccine did not prolong survival or delay recurrence. In the United States one product of this kind is approved, for some men with advanced prostate cancer. Treat promised success figures with caution and ask which studies they come from.

Is dendritic cell therapy approved in Germany?

No dendritic cell vaccine is licensed in Germany as a ready-made medicine for general use. Each vaccine is made for one patient in a laboratory with a manufacturing authorisation, and the Paul-Ehrlich-Institut grants permits for such individually made cell-based products. Ask the clinic on what basis the vaccine is made: under such a permit or in an approved clinical trial.

Can the vaccine be combined with chemotherapy or other immunotherapy?

Yes: the vaccine is used alongside standard treatment, not instead of it, but the oncologist sets the order and timing, because some medicines, such as corticosteroids, weaken the immune response. Combinations with checkpoint inhibitors are being tested in clinical trials and cannot yet be considered proven outside them.

How AlenMed organises dendritic cell therapy

AlenMed starts by asking whether a vaccine makes sense: it sends reports, histology and imaging to an oncologist at a partner clinic, who assesses whether a vaccine or a clinical trial is an option and which standard treatment should come first.

If the doctor sees grounds for it, AlenMed coordinates dates for leukapheresis, laboratory work and injection visits, provides an interpreter at appointments and arranges the visa invitation. AlenMed’s office is in Munich; partner clinics are all over Germany.

This material is for information only and is not an offer. Whether a dendritic cell vaccine is appropriate is decided by a doctor after an in-person examination, and no result is promised.

News on this topic

All news